The Impact of Epstein–Barr Virus Serostatus Mismatch in Adult Kidney Transplant Recipients: An Analysis of the 2012–2022 OPTN Database
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Namrata Parikh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Lymphoproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background and Aims One strategy to minimize the risk of posttransplant lymphoproliferative disorder (PTLD) is to avoid an Epstein–Barr Virus (EBV) mismatch through kidney paired donation. We aimed to estimate the incidence of PTLD in EBV‐negative kidney transplant recipients with EBV‐positive donors (D+/R−) and evaluate the excess risk of death following the occurrence of PTLD.
Methods
We included adult patients in OPTN database who underwent kidney transplants between 2012 and 2022. Cox regression analysis was employed to evaluate the impact of EBV serostatus on the development of PTLD, and to assess mortality following PTLD diagnosis in D+/R− individuals.
Results
A total of 179 068 patients were included, with 92.8% in the R+, 6.4% in the D+/R−, and 0.8% in the D−/R− group. D+/R− exhibited a significantly higher risk of PTLD compared to R+ and D−/R− groups. D+/R− had a greater risk of PTLD when compared to D−/R− recipients (aHR: 3.82; p < 0.001). Among D+/R− recipients, those who developed PTLD had a significantly higher risk of mortality (aHR: 2.28; p < 0.001 in deceased donor kidney transplant [DDKT] and aHR: 5.22; p < 0.001 in living donor kidney transplant [LDKT]).
Conclusions
D+/R− recipients have nearly a fourfold higher risk of PTLD compared to D−/R− recipients, suggesting that choosing an EBV D−/R− transplant could reduce the PTLD risk by about 73%. This data is crucial for counseling EBV‐negative patients considering kidney paired donation to avoid an EBV serostatus mismatch.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Transplant, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Namrata Parikh, Rose Mary Attieh, Hani M Wadei, Michael A Mao, Shennen A Mao, Cemal Burcin Taner, Tambi Jarmi, Wisit Cheungpasitporn, Napat Leeaphorn
Zitieren
APA
Parikh, N., Attieh, R. M., Wadei, H. M., Mao, M. A., Mao, S. A., Taner, C. B., Jarmi, T., Cheungpasitporn, W., & Leeaphorn, N. (2025). The Impact of Epstein–Barr Virus Serostatus Mismatch in Adult Kidney Transplant Recipients: An Analysis of the 2012–2022 OPTN Database. Clinical Transplantation. https://doi.org/10.1111/ctr.70117
Vancouver
Parikh N, Attieh RM, Wadei HM, Mao MA, Mao SA, Taner CB, et al. The Impact of Epstein–Barr Virus Serostatus Mismatch in Adult Kidney Transplant Recipients: An Analysis of the 2012–2022 OPTN Database. Clinical Transplantation. 2025. doi:10.1111/ctr.70117
BibTeX
@article{Parikh2025,
author = {Parikh, Namrata and Attieh, Rose Mary and Wadei, Hani M and Mao, Michael A and Mao, Shennen A and Taner, Cemal Burcin and Jarmi, Tambi and Cheungpasitporn, Wisit and Leeaphorn, Napat},
title = {The Impact of Epstein–Barr Virus Serostatus Mismatch in Adult Kidney Transplant Recipients: An Analysis of the 2012–2022 OPTN Database},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70117}
}
EUVIMED